مصطلحات الفهرس: herpes zoster/si [Side Effect], human, human cell, hypertension/si [Side Effect], leukemia relapse, limb injury/si [Side Effect], limit of quantitation, liquid chromatography mass spectrometry, lymph node biopsy, lymphadenopathy, lymphocyte count, lymphocytic lymphoma/dt [Drug Therapy], lymphocytosis, major clinical study, male, maximum plasma concentration, maximum tolerated dose, multicenter study, muscle spasm/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], open study, peripheral blood mononuclear cell, peripheral edema/si [Side Effect], petechia/si [Side Effect], pharmacodynamics, pharmacokinetic parameters, phase 1 clinical trial, plasma concentration-time curve, pneumonia/si [Side Effect], priority journal, progression free survival, purpura/si [Side Effect], rash/si [Side Effect], rhinopharyngitis/si [Side Effect], sinusitis/si [Side Effect], squamous cell skin carcinoma/si [Side Effect], subcutaneous hemorrhage/si [Side Effect], therapeutic dose, therapy delay, thrombocytopenia/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], very elderly, X-ray computed tomography, xerostomia/si [Side Effect], acetylsalicylic acid, alemtuzumab, bendamustine, chlorambucil, clopidogrel, cyclophosphamide, doxorubicin, duvelisib, fludarabine, heparin, idelalisib, lenalidomide, low molecular weight heparin, navitoclax, nonsteroid antiinflammatory agent, obinutuzumab, ofatumumab, pentostatin, prednisone, rituximab, thrombin inhibitor, venetoclax, vincristine, zanubrutinib/ae [Adverse Drug Reaction], zanubrutinib/ct [Clinical Trial], zanubrutinib/dt [Drug Therapy], zanubrutinib/to [Drug Toxicity], zanubrutinib/po [Oral Drug Administration], zanubrutinib/pk [Pharmacokinetics], zanubrutinib/pd [Pharmacology], postprocedural contusion/si [Side Effect], drug half life, abdominal pain/si [Side Effect], acute kidney failure/si [Side Effect], adult, aged, anemia/si [Side Effect], area under the curve, arthralgia/si [Side Effect], article, backache/si [Side Effect], basal cell carcinoma/si [Side Effect], cancer patient, cancer survival, cellulitis/si [Side Effect], chronic lymphatic leukemia/dt [Drug Therapy], clinical outcome, cohort analysis, constipation/si [Side Effect], contusion/si [Side Effect], coughing/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation, dizziness/si [Side Effect], drug blood level, drug dose escalation, drug efficacy, drug safety, drug tolerability, fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, follow up, headache/si [Side Effect], hematuria/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35986Test
Blood
Click here for full text options
LibKey Link

مصطلحات الفهرس: creatinine/ec [Endogenous Compound], aged, all cause mortality, article, cancer growth, cancer mortality, cancer survival, chronic lymphatic leukemia/dt [Drug Therapy], clinical article, creatinine clearance, drug safety, female, follow up, gene, gene deletion, gene mutation, human, infection/si [Side Effect], male, neutropenia/si [Side Effect], open study, phase 3 clinical trial, priority journal, progression free survival, rating scale, scoring system, treatment duration, chlorambucil/ae [Adverse Drug Reaction], chlorambucil/ct [Clinical Trial], chlorambucil/cb [Drug Combination], chlorambucil/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/cb [Drug Combination], obinutuzumab/dt [Drug Therapy], venetoclax/ae [Adverse Drug Reaction], venetoclax/ct [Clinical Trial], venetoclax/cb [Drug Combination], venetoclax/dt [Drug Therapy], TP53 gene, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35653Test
New England Journal of Medicine
Click here for full text options
LibKey Link

مصطلحات الفهرس: herpes zoster/si [Side Effect], human, human cell, hypertension/si [Side Effect], leukemia relapse, limb injury/si [Side Effect], limit of quantitation, liquid chromatography mass spectrometry, lymph node biopsy, lymphadenopathy, lymphocyte count, lymphocytic lymphoma/dt [Drug Therapy], lymphocytosis, major clinical study, male, maximum plasma concentration, maximum tolerated dose, multicenter study, muscle spasm/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], open study, peripheral blood mononuclear cell, peripheral edema/si [Side Effect], petechia/si [Side Effect], pharmacodynamics, pharmacokinetic parameters, phase 1 clinical trial, plasma concentration-time curve, pneumonia/si [Side Effect], priority journal, progression free survival, purpura/si [Side Effect], rash/si [Side Effect], rhinopharyngitis/si [Side Effect], sinusitis/si [Side Effect], squamous cell skin carcinoma/si [Side Effect], subcutaneous hemorrhage/si [Side Effect], therapeutic dose, therapy delay, thrombocytopenia/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], very elderly, X-ray computed tomography, xerostomia/si [Side Effect], acetylsalicylic acid, alemtuzumab, bendamustine, chlorambucil, clopidogrel, cyclophosphamide, doxorubicin, duvelisib, fludarabine, heparin, idelalisib, lenalidomide, low molecular weight heparin, navitoclax, nonsteroid antiinflammatory agent, obinutuzumab, ofatumumab, pentostatin, prednisone, rituximab, thrombin inhibitor, venetoclax, vincristine, zanubrutinib/ae [Adverse Drug Reaction], zanubrutinib/ct [Clinical Trial], zanubrutinib/dt [Drug Therapy], zanubrutinib/to [Drug Toxicity], zanubrutinib/po [Oral Drug Administration], zanubrutinib/pk [Pharmacokinetics], zanubrutinib/pd [Pharmacology], postprocedural contusion/si [Side Effect], drug half life, abdominal pain/si [Side Effect], acute kidney failure/si [Side Effect], adult, aged, anemia/si [Side Effect], area under the curve, arthralgia/si [Side Effect], article, backache/si [Side Effect], basal cell carcinoma/si [Side Effect], cancer patient, cancer survival, cellulitis/si [Side Effect], chronic lymphatic leukemia/dt [Drug Therapy], clinical outcome, cohort analysis, constipation/si [Side Effect], contusion/si [Side Effect], coughing/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation, dizziness/si [Side Effect], drug blood level, drug dose escalation, drug efficacy, drug safety, drug tolerability, fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, follow up, headache/si [Side Effect], hematuria/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35986Test
Blood
LibKey Link

مصطلحات الفهرس: cyclophosphamide, follicular lymphoma/dt [Drug Therapy], fludarabine, Fc receptor/ec [Endogenous Compound], cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine, acute lymphoblastic leukemia/dt [Drug Therapy], amino acid sequence, ANCA associated vasculitis/dt [Drug Therapy], antigen binding, antineoplastic activity, B cell lymphoma/dt [Drug Therapy], Burkitt lymphoma/dt [Drug Therapy], cancer immunization, cell killing, chronic lymphatic leukemia/dt [Drug Therapy], clinical trial (topic), complement dependent cytotoxicity, diffuse large B cell lymphoma/dt [Drug Therapy], down regulation, drug mechanism, drug receptor binding, event free survival, hematologic malignancy/dt [Drug Therapy], human, humoral immune deficiency/dt [Drug Therapy], idiopathic thrombocytopenic purpura/dt [Drug Therapy], immune response, immunomodulation, immunosuppressive treatment, lack of drug effect, leukemia/si [Side Effect], lymphocytic lymphoma/dt [Drug Therapy], lymphoproliferative disease/dt [Drug Therapy], marginal zone lymphoma/dt [Drug Therapy], molecularly targeted therapy, overall survival, partial drug response, pharmacokinetic parameters, progression free survival, protein degradation, protein expression, randomized controlled trial (topic), methotrexate, obinutuzumab/dt [Drug Therapy], ocrelizumab, ofatumumab/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/dt [Drug Therapy], tumor antigen/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], veltuzumab, CD20 antibody, B lymphocyte receptor/ec [Endogenous Compound], systemic lupus erythematosus/dt [Drug Therapy], smoldering multiple myeloma/dt [Drug Therapy], rheumatoid arthritis/dt [Drug Therapy], review, recombinant DNA technology, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36922Test
Human Vaccines and Immunotherapeutics
Click here for full text options
LibKey Link

مصطلحات الفهرس: creatinine/ec [Endogenous Compound], aged, all cause mortality, article, cancer growth, cancer mortality, cancer survival, chronic lymphatic leukemia/dt [Drug Therapy], clinical article, creatinine clearance, drug safety, female, follow up, gene, gene deletion, gene mutation, human, infection/si [Side Effect], male, neutropenia/si [Side Effect], open study, phase 3 clinical trial, priority journal, progression free survival, rating scale, scoring system, treatment duration, chlorambucil/ae [Adverse Drug Reaction], chlorambucil/ct [Clinical Trial], chlorambucil/cb [Drug Combination], chlorambucil/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/cb [Drug Combination], obinutuzumab/dt [Drug Therapy], venetoclax/ae [Adverse Drug Reaction], venetoclax/ct [Clinical Trial], venetoclax/cb [Drug Combination], venetoclax/dt [Drug Therapy], TP53 gene, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35653Test
New England Journal of Medicine
LibKey Link

مصطلحات الفهرس: cyclophosphamide, follicular lymphoma/dt [Drug Therapy], fludarabine, Fc receptor/ec [Endogenous Compound], cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine, acute lymphoblastic leukemia/dt [Drug Therapy], amino acid sequence, ANCA associated vasculitis/dt [Drug Therapy], antigen binding, antineoplastic activity, B cell lymphoma/dt [Drug Therapy], Burkitt lymphoma/dt [Drug Therapy], cancer immunization, cell killing, chronic lymphatic leukemia/dt [Drug Therapy], clinical trial (topic), complement dependent cytotoxicity, diffuse large B cell lymphoma/dt [Drug Therapy], down regulation, drug mechanism, drug receptor binding, event free survival, hematologic malignancy/dt [Drug Therapy], human, humoral immune deficiency/dt [Drug Therapy], idiopathic thrombocytopenic purpura/dt [Drug Therapy], immune response, immunomodulation, immunosuppressive treatment, lack of drug effect, leukemia/si [Side Effect], lymphocytic lymphoma/dt [Drug Therapy], lymphoproliferative disease/dt [Drug Therapy], marginal zone lymphoma/dt [Drug Therapy], molecularly targeted therapy, overall survival, partial drug response, pharmacokinetic parameters, progression free survival, protein degradation, protein expression, randomized controlled trial (topic), methotrexate, obinutuzumab/dt [Drug Therapy], ocrelizumab, ofatumumab/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/dt [Drug Therapy], tumor antigen/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], veltuzumab, CD20 antibody, B lymphocyte receptor/ec [Endogenous Compound], systemic lupus erythematosus/dt [Drug Therapy], smoldering multiple myeloma/dt [Drug Therapy], rheumatoid arthritis/dt [Drug Therapy], review, recombinant DNA technology, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36922Test
Human Vaccines and Immunotherapeutics
LibKey Link

مصطلحات الفهرس: priority journal, progression free survival, renal clearance, bendamustine, chlorambucil, creatinine/ec [Endogenous Compound], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], fludarabine/cb [Drug Combination], fludarabine/dt [Drug Therapy], ibrutinib, immunoglobulin heavy chain/ec [Endogenous Compound], obinutuzumab, rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], chronic lymphatic leukemia/dt [Drug Therapy], cancer combination chemotherapy, cancer control, cancer immunotherapy, cancer mortality, cancer patient, cancer survival, clinical outcome, clinical practice, creatinine clearance, human, letter, overall survival, Letter

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38275Test
Journal of Clinical Oncology
Click here for full text options
LibKey Link

مصطلحات الفهرس: priority journal, progression free survival, renal clearance, bendamustine, chlorambucil, creatinine/ec [Endogenous Compound], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], fludarabine/cb [Drug Combination], fludarabine/dt [Drug Therapy], ibrutinib, immunoglobulin heavy chain/ec [Endogenous Compound], obinutuzumab, rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], chronic lymphatic leukemia/dt [Drug Therapy], cancer combination chemotherapy, cancer control, cancer immunotherapy, cancer mortality, cancer patient, cancer survival, clinical outcome, clinical practice, creatinine clearance, human, letter, overall survival, Letter

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38275Test
Journal of Clinical Oncology
Click here for full text options
LibKey Link

مصطلحات الفهرس: case report, chronic lymphatic leukemia/dt [Drug Therapy], colonoscopy, corticosteroid therapy, cytomegalovirus infection/di [Diagnosis], cytomegalovirus infection/dt [Drug Therapy], cytomegalovirus infection/si [Side Effect], dehydration, diarrhea, drug surveillance program, drug withdrawal, enterocolitis/si [Side Effect], gastrointestinal infection/di [Diagnosis], gastrointestinal infection/dt [Drug Therapy], gastrointestinal infection/si [Side Effect], gastroscopy, hospital discharge, human, human tissue, letter, lymphocyte count, male, mild renal impairment, treatment indication, treatment response, very elderly, ganciclovir/dt [Drug Therapy], ganciclovir/iv [Intravenous Drug Administration], idelalisib/ae [Adverse Drug Reaction], idelalisib/dt [Drug Therapy], rituximab/dt [Drug Therapy], anemia, valganciclovir/po [Oral Drug Administration], biopsy, valganciclovir/dt [Drug Therapy], aged, Letter

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38486Test
Pathology
Click here for full text options
LibKey Link

مصطلحات الفهرس: case report, chronic lymphatic leukemia/dt [Drug Therapy], colonoscopy, corticosteroid therapy, cytomegalovirus infection/di [Diagnosis], cytomegalovirus infection/dt [Drug Therapy], cytomegalovirus infection/si [Side Effect], dehydration, diarrhea, drug surveillance program, drug withdrawal, enterocolitis/si [Side Effect], gastrointestinal infection/di [Diagnosis], gastrointestinal infection/dt [Drug Therapy], gastrointestinal infection/si [Side Effect], gastroscopy, hospital discharge, human, human tissue, letter, lymphocyte count, male, mild renal impairment, treatment indication, treatment response, very elderly, ganciclovir/dt [Drug Therapy], ganciclovir/iv [Intravenous Drug Administration], idelalisib/ae [Adverse Drug Reaction], idelalisib/dt [Drug Therapy], rituximab/dt [Drug Therapy], anemia, valganciclovir/po [Oral Drug Administration], biopsy, valganciclovir/dt [Drug Therapy], aged, Letter

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38486Test
Pathology
Click here for full text options
LibKey Link